 |
Hypothyroidism In Women Associated With Liver Cancer |
|
Sustained Response Seen with New Hepatitis C Drug |
|
Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron) |
|
Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C |
|
Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C |
|
HCV Vaccine Development |
|
Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage |
|
Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C |
|
Response To Therapy In Chronic Hepatitis C Predicted By 2-Day Results |
|
Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors |
|
Hepatitis C Linked to Increased Risk of Intrahepatic Cholangiocarcinoma |
|
Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA |
|
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study with R7128 in Treatment Naive HCV Patients |
|
Human Genome Sciences Announces Initiation of Phase 2b Trial 0f Albuferon Dosed Monthly in Chronic Hepatitis C |
|
Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues |
|
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C |
|
Pegylated interferon alpha2a is more effective in some hepatitis C patients with specific genotypes than the alpha2b form of the drug, an Italian researcher said |
|
HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers |
|
Hepatitis C patients may have abnormal blood sugar |
|
FDA Approves Nexavar for Patients with Inoperable Liver Cancer |
|
Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years |
|
Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C |
|
Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients |
|
Insulin Resistance Independently Associated With Chronic Hepatitis C |
|
Pathology of Chronic Hepatitis C in Children: Peds-C Trial |
|
Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users |
|
Acute Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children |
|
How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50? |
| |
Go to top |
|
Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians |
|
HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C |
|
Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients with Chronic Hepatitis C |
|
Use of Epoetin (EPO) to Manage Anemia in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin |
|
Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis |
|
HCV Care by Liver Specialists or Community-Based Practices: Pro & Con |
|
Decreased HCV-specific Immunity in African-Americans May Help Explain Poorer Response to Antiviral Therapy |
|
400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV |
|
Liver Stiffness Predicts Portal Hypertension in HCV Cirrhosis |
|
EASL: Sustained Virologic Response Equals Cure for HCV Infection |
|
Racial Differences Seen In Steatosis In Patients With Hepatitis C |
|
New Vaccine Schedule Offers Protection Against Hepatitis A And Hepatitis B |
|
Interferon Gamma Does Not Reverse Fibrosis in Hepatitis C Patients with Advanced Liver Disease |
|
Hepatitis C in African Americans |
|
Three Studies Examine Syringe Exchange Policies in the U.S. |
|
Short-course Pegylated Interferon for Acute Hepatitis C |
|
Heavy-Drinking Women with HCV Infection Cut Decade Off Life |
|
Treatment Response in Cirrhotic Hepatitis C Patients with Portal Hypertension |
|
Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment |
|
Rapid Decline of HCV RNA in Patients Treated with VX-950 |
|
Predicting Survival After Liver Transplant |
|
Patients Who Recover from Hepatitis C Have Lower Risk of Reinfection |
| |
Go to top |
|
New Therapy Significantly Increases Platelet Count |
|
Is Hepatitis A and B Screening and Vaccination in Chronic Hepatitis C Patients Effective? |
|
Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients |
|
Baseline HCV RNA of 400,000 Best Predicts SVR and Relapse Rates in Patients Treated with Pegasys plus Ribavirin |
|
Hepatitis C Treatment and New Drugs in Development |
|
Immunological Control of Hepatitis C Virus during Acute Infection |
|
New Treatments Improve Hepatocellular Carcinoma Survival |
|
Gene Response to Interferon Therapy for Heaptitis C Differe by Race |
|
Effect of Tattooing, Body Piercing and Intranasal Drug Use on Risk of HCV and HBV Infection |
|
Treating Hepatitis C Recurrence After Liver Transplantation |
| |
Go to top |
|
PEGASYSŪ ACCELERATE Trial Shows Six Months of Treatment Is Optimal
for Achieving Success in Category of Hepatitis C Patients |
|
New Oral Polymerase Inhibitor Shows Promising Results in Chronic
Hepatitis C Patients |
|
Genetic Test to Give Clues on Treatment of Hepatitis C |
|
Schering-Plough
Reports FDA Grants Fast Track Designation to Oral HCV Protease
Inhibitor SCH 503034 |
|
African
Americans and Hepatitis C Virus Infection |
|
FDA
Grants Fast Track Designation to VX-950, an Experimental Oral
Hepatitis C Virus Protease Inhibitor from Vertex |
|
Comorbidites
among Individuals with HCV Infection Are often Cited as Reason
for Excluding Patients from Access to Anti-HCV Treatment |
|
Hispanic
Race/Ethnicity is Associated with an Aggressive Course of Chronic
Hepatitis C Infection: Role of Patient Demographics, Hepatic
Steatosis and Necroinflammation |
|
INTERNAL
MEDICINE RESIDENTS KNOWLEDGE AND MANAGEMENT OF HEPATITIS C VIRUS
(HCV) INFECTION IMPROVE WITH A TARGETED EDUCATIONAL INTERVENTION |
|
Chronic
Hepatitis C in the Elderly
|
| |
Go to top |
|
The
Effect of Ribavirin on Bone Density in Children with Chronic
Hepatitis C Treated with Interferon-Ribavirin |
|
Liver
Cirrhosis- and Hepatitis C Virus-related Brain Disease |
|
Acute
HCV Infection: Diagnosis, Natural History and Treatment |
|
Chronic
Hepatitis C in Latinos |
|
Hepatitis
C Virus Infection Contributes to Gallstone Formation |
|
Clinical
Utility of Viral Load Measurements in Individuals with Chronic
Hepatitis C on Antiviral Therapy |
|
A
Dose Escalation Study of Merimepodib (VX-497) Plus Interferon
Alfa among Treatment-naïve |
|
Insulin
resistance is a cause of steatosis and fibrosis progression
in chronic hepatitis C |
|
Response
to Interferon Alfa Therapy in a Patient with HCV-related Arthritis |
|
Treatment
for Hepatitis C in Substance Users |
|
Acetaminophen,
When Taken as Directed, is Safe for Patients with Liver Disease
|
| |
Go to top |
|
Predictors
of Treatment Failure in Patients with Hepatitis C Genotypes
2 or 3 |
|
Statins
Protect Against Hepatocellular Cancer in Patients with Hepatitis
C |
|
VX-950
- A Powerful Punch |
|
Viramidine
Demonstrates Anti-HCV Genotype 1 Activity That Compares Favorably
to Ribavirin, But without Complications of Severe Anemia |
|
Peginterferon
Alfa-2a (Pegasys) Does Not Alter the Pharmacokinetics of Methadone |
|
Scientists
Replicate Hepatitis C Virus In Laboratory |
|
Relationship
Between Serum Ferritin, Hepatic Iron Staining, Diabetes Mellitus
and Fibrosis Progression in Patients with Chronic Hepatitis
C |
|
Alcohol,
tobacco, and obesity act synergistically to increase the risk
of HCC Print |
|
Nine
of 10 Chronic Hepatitis C Patients Achieve a Cure 24 Weeks Post-treatment
with High Dose Ribavirin Plus Standard Dose Peginterferon Alfa-2a
(Pegasys) |
|
Interferon
Slows Hep C Progression: Research Confirms Low-Dose Therapy
Works for Long-Term Maintenance |
|
A
Pilot Study of Combination Treatment with Consensus Interferon
(Infergen) and Interferon Gamma 1b (Actimmune) in Nonresponders
to Peginterferon Plus Ribavirin |
|
Treatment
for 14 Weeks with Pegylated Interferon Alfa-2b (Peg-Intron)
and Ribavirin in HCV Infection with Genotype 2 or 3 |
|
Is
There a Correlation Between HCV Viral Load and Severity of Liver
Disease? |
|
A
Multicenter Study of the Usefulness of Liver Biopsy in Hepatitis
C |
|
Epoetin
Alfa Treatment for Acute Anemia During Interferon plus Ribavirin
Combination Therapy |
|
Prolongation
of HCV Treatment to 18 Months Reduces Relapse Rates From 40
to 15 Percent |
| |
Go to top |
|
Sudden
Hearing Loss in Patients with Chronic Hepatitis C Treated with
Pegylated Interferon/Ribavirin |
|
Environmental
stability of Hepatitis C Virus (HCV): Viability of dried/stored
HCV in chimpanzee infectivity studies |
|
Peginterferon
Alfa-2a (Pegasys) and Ribavirin for Black American Patients
with Chronic HCV Genotype 1 |
|
Twice
a Week Administration of PEG-Intron Plus Ribavirin in Obtaining
SVR Among Patients with HCV Genotype 1 |
|
Anemia
Is a Major Determinant of Fatigue in Patients with Cirrhosis
|
|
Lack
of Evidence of Sexual Transmission of Hepatitis C Among Monogamous
Couples: Results of a Ten-Year Prospective Follow-Up Study |
|
Treatment
Practices Regarding Management of Patients with Hepatitis C
Infection Non-Responders to Antiviral Therapy |
|
Hepatitis
C a Direct Cause of Diabetes |
|
As
Testing Campaigns Identify More People With Asymptomatic Hepatitis
C Infection, Benefits, Risks and Cost-Effectiveness of Early
Treatment Uncertain |
|
Mild
Hepatitis C Infection Will Rapidly Worsen in 1 in 3 People Affected |
|
Extrahepatic
Manifestations of Hepatitis C Among United States Male Veterans
|
|
Global
Burden of Disease Associated with Hepatitis C |
|
PEG-Intron
in Combination with Ribavirin Produces Sustained Viral Response
of 81% in Genotype 4 Patients with HCV Viral Load Less Than
2 X 10 |
|
Retreatment
of Patients with Chronic Hepatitis C |
|
New
Study Investigates Pegasys(R) and Copegus(R) for the Treatment
of Chronic Hepatitis C in African Americans |
|
Treating
Methadone Patients |
| |
Go to top |
|
Maintenance
therapy with ribavirin in patients with chronic hepatitis C
who fail to respond to combination therapy with interferon alfa
and ribavirin |
|
High
body mass index an independent risk factor for nonresponse to
antiviral treatment in chronic hepatitis C |
|
Pharmacokinetics
of Pegasys Compared to PEG-Intron in Treatment-Naïve Patients
with Chronic Hepatitis C |
|
Is
Treatment of Chronic Hepatitis C Feasible in Patients on Methadone
Maintenance? |
|
Hepatic
Steatosis Is a Significant Risk Factor for Hepatocellular Carcinoma
in Patients with Chronic HCV |
|
Management
of HCV Treatment Failure |
|
IL-12
Not Useful |
|
News
from Hepatitis Week of May 25, 2003 / Vol. 3 No. 21 Study: Peginterferon
Alfa-2a Effective and Safe for Children |
|
Pharmacokinetics,
Pharmacodynamics and Antiviral Response in Patients with Chronic
Hepatitis C Infection on Methadone Maintenance Therapy Receiving
Pegasys (peginterferon alfa-2a) |
|
Adherence
and Mental Side Effects During HCV Treatment with Interferon
Alfa and Ribavirin in Psychiatric Risk Groups |
|
Comparison
in the Progression of Liver Fibrosis in HCV Patients with Normal
and Elevated Transaminase (ALT) |
|
Low
Sustained HCV Eradication Rate from Triple Combination of Interferon
Alfa-2b, Ribavirin and Amantadine |
|
Pharmacokinetics
of Pegasys Compared to PEG-Intron in Treatment-Naïve Patients
with Chronic Hepatitis C |
|
Pediatric
Hepatitis C Is Mild But Persistent |
|
Cerebral
dysfunction in chronic hepatitis C infection |
|
Rate
of natural disease progression |
|
Pregnancy
& HCV
Medscape Gastroenterology 5(1), 2003. © 2003 Medscape |
|
Adherence
and Mental Side Effects During Hepatitis C Treatment |
|
Maintenance
Therapy with Pegasys Monotherapy or Pegasys + Ribavirin in Genotype
1 HCV Patients After 24-Week Response |
|
COBAS
Ampliscreen
SOURCE Roche Diagnostics Corporation |
|
Large
Study Finds Significant Association Between HCV and Extrahepatic
Disorders |
|
FDA
Panel Unanimously Votes for the Approvability of Pegasys/ Copegus
For the Treatment of Hepatitis C
Alan Franciscus |
|
Liver
transplantation for patients on methadone maintenance |
|
HCV
Maintenance Therapy From Hep C Advocate
Liz Highleyman, Contributing Editor ©2002 - Hepatitis
C Support Project/HCV Advocate |
|
Pegasys
Fast-Tracked by FDA
By Michael Shields |
|
Women
and HCV
American Journal of Epidemiology, 155 (7), 645-53, April
1, 2002 |
|
The
Importance of Laboratory Test Results in Hepatitis C Infection
©2002 - Hepatitis
C Support Project/HCV Advocate |
|
Fatigue
Is Associated with High Circulating Leptin Levels in Chronic
Hepatitis C |
|
Fatigue,
HCV/HIV Coinfection, Transmission, Disease Progression &
Interferon |
|
Alpha
Feto-Protein Levels in Hepatitis C Subjects Treated with Combination
Therapy: Abnormal Levels Decline with Therapy |
|
Does
High Body Mass Index Affect Hepatic Fibrosis, Steatosis and
Inflammation in Patients with Chronic Hepatitis C? |
|
Treatment
of Acute Hepatitis C
Journal of Gastroenterology, Apr 2002 |
|
The
Impact of Intervening Substance Abuse on Hepatitis C Treatment
Outcomes in Recovering Injection Drug Users: An Interim Analysis
Diana L. Sylvestre, Barry J. Clements, Oakland, CA |
|
Does
Normal ALT Exclude Severe Hepatic Fibrosis in Patients with
Chronic Hepatitis C? |
|
Pegylated
Interferon alfa-2b and Ribavirin for the Treatment of Chronic
Hepatitis C Infection in African Americans and Non-Hispanic
Whites. A Preliminary Report |
|
Pegylated
Interferon Alfa 2b (PEG-IFN) and Ribavirin for Hepatitis C Patients
who Were Nonresponders to Previous Therapy |
|
Interferon
Alfa-2b and Ribavirin for Patients with Chronic Hepatitis C
and Normal ALT: Final Results |
|
The
Story of Ribavirin
Author: Johnson Lau in Hepatology (may 2002, Volume 35,
Number 5) |
|
Simple
blood tests can predict compensated liver cirrhosis in patients
with chronic hepatitis C.
Hepatogastroenterology 2002 Mar-Apr;49(44):478-81 |
|
Incidence
of hepatocellular carcinoma in chronic hepatitis C after interferon
therapy.
Hepatogastroenterology 2002 Mar-Apr;49(44):508-12 |
|
The
Impact of Pegylated Interferon Alfa-2b and Ribavirin on Liver
Fibrosis
Gastroenterology 2002 May;122(5):1303-1313 |
|
Decreased
Bone Mineral Density In Non-cirrhotic Patients With Chronic
Hepatitis B or C
2002 EASL Conference |
| |
Go to top |
|
Treating
the Methadone Patient
©2002 - Hepatitis
C Support Project/HCV Advocate |
|
Treatment
with Pegylated Interferon May Cause Eye Complications in Patients
with Chronic Hepatitis C
From HIV and Hepatitis.com |
|
Smoking
and Alanine Aminotransferase Levels in Hepatitis C Virus Infection
|
|
Quality
of Life During Treatment of HCV Is Better with Pegylated Interferons
By Brian Boyle, MD |
|
A
new report underscores the risks injection drug users face for
infection with the hepatitis C virus (HCV) from sharing commonly
used drug paraphernalia other than syringes, such as drug "cookers"
and cotton filters.
SOURCE: American Journal of Epidemiology |
|
HEPATOLOGY
WATCH® - Timely Information for Practicing Physicians SPECIAL
ISSUE: HIGHLIGHTS OF ROCHE SATELLITE SYMPOSIA OCTOBER 19, 2001
acg ANNUAL MEETING: PROGRESS IN THE MANAGEMENT OF HEPATITIS
C NOVEMBER 12, 2001 AASLD ANNUAL MEETING: PEGYLATED INTERFERONS
IN HCV – TREATMENT OUTCOMES |
|
Screening
middle-age Americans for hepatitis C could cut medical costs
and increase life expectancy for the people found to have the
potentially fatal disease, says new research from the University
of Michigan Health System.
SATURDAY, Feb. 9 (HealthScoutNews) |
|
Sexual
Transmission of HCV
©2002 - Hepatitis
C Support Project/HCV Advocate |
|
Hepatitis
C & Rheumatic Manifestations
NEW YORK (Reuters Health) Feb 18 |
|
The
HCV and HIV Coinfected Patient: What Have We Learned About athophysiology?
Andrew H. Talal, MD, MPH, P. Wilfredo Canchis, MD, and Ira M.
Jacobson, MD; Weill College of Medicine, Cornell university,
NYC |
|
Heavy
Drinking Raises Risk of Liver Cancer: Study
By Melissa Schorr NEW YORK (Reuters Health) |
|
Liver
transplantation and opioid dependence
Journal of the American Medical Association |
|
Hepatitis
C & Glomerulonephritis
A comprehensive study of the association between hepatitis C
virus and glomerulopathy |
| |
Go to top |
|
Race
influences liver transplant survival in US
NEW YORK, Jan 25 (Reuters Health) |
|
Menopause
May Accelerate Liver Fibrosis; Perhaps Hormone Replacement Therapy
Can Be Helpful |
|
Specialized
Care for HCV Improves Survival in HIV/HCV Co-Infected Patients
By Brian Boyle, MD |
|
HIV/HCV
Co-Infected Patients Respond Well to HCV Therapy
By Brian Boyle, MD |
|
Organ
network adopts new patient-ranking system
WASHINGTON, Nov 16 (Reuters Health) |
|
Can
Cirrhotics Achieve a Histologic Response? |
|
Viral
Load at Week 12 and Reduction in Viral Load in First 12 weeks
of Therapy is Useful in Predicting Response
Mitchell L. Shiffman, Medical College of Virginia |
|
Pegylated
Interferon Superior to Standard Interferon (Again) in the Treatment
of Hepatitis C
By Brian Boyle, MD |
|
Things
your doctor should be doing: Chronic viral hepatitis C: management
update
Chronic viral hepatitis C: management update Klaus S. Gutfreund,
Vincent G. Bain CMAJ 2000;162(6):827-33 |
|
Roche
Licenses Potential Second-Generation Drug From ICN to Set New
Standards In Hepatitis C Treatment
BASEL, Switzerland, July 2 /PRNewswire |
|
FDA
Approves PCR Test
INDIANAPOLIS, July 9 /PRNewswire |
|
The
Long and Short of Transfusion Hepatitis
The American College of Gastroenterology T. McCashland, M.D.
June 2001 |
|
Controlling
Pain in Liver Biopsy, or "We Will Probably Need to Repeat
the Biopsy in a Year or Two to Assess the Response"
The American College of Gastroenterology Stephen H. Caldwell,
M.D May 2001 |
|
New
Federal Rules for Methadone Maintenance Clinics
WASHINGTON, DC - CSAT News Release; January 17, 2001 |
|
Hepatitis
C Increases Diabetes Risk
NEW YORK, Oct 16 (Reuters Health)
SOURCE: Annals of Internal Medicine 2000;133:592-599. |
|
Fatigue
Of Chronic Hepatitis C Infection Severe And Intransigent
J Clin Gastroenterol 2001;32(5):413-417. "Assessment
of Fatigue and Psychologic Disturbances in Patients with Hepatitis
C Virus Infection" By Robert Short |
|
Peginterferon
Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
New England Journal of Medicine |
|
The
Antifibrotic Effect of Interferon Alfa in the Treatment of Chronic
Hepatitis C:
An Unanticipated but Important End Point
Jean-Francois J. Dufour, MD, and Marshall M. Kaplan, MD,
University of Bern, Switzerland, and Tufts University School
of Medicine, Boston, Mass. |
|
Pegasys
Plus Ribavirin Appears Superior to Rebetron Combination Therapy
for Chronic HCVCV
Digestive Diseases Week Conference 2001 |
|
Long-term
administration of interferon in hepatitis C virus (HCV)-related
cirrhosis
Department of Gastroenterology, Toranomon Hospital and Okinaka
Memorial Institute for Medical Research, Tokyo, Japan |
|
Doctors/Patients
Not Following Through on Hepatitis C Screening, Diagnosis and
Referral
University of Michigan Health System, via DG Dispatch |
| |
Go to top |
